Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab plus IMRT for resectable locally advanced hepatocellular carcinoma with macrovascular invasion
ChiCTR2000036385Phase 2Completed
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: Objective response rate and Overall survival. Started Oct 2020; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000036385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036385.